Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - What's Next?

Key Points

• Capricor's shares were down 6.5% intraday, trading as low as $31.39 (last at $31.395) on about 545,932 shares, roughly 57% below its average daily volume.
• Analysts have largely raised targets—B. Riley to $63, Piper Sandler to $58, Cantor Fitzgerald to $62 and HC Wainwright to $60—leaving a MarketBeat consensus of Moderate Buy with a $46.09 consensus price target.
• The company missed quarterly EPS (−$0.62 vs. −$0.51 expected) and has seen notable insider selling, with 147,529 shares sold (~$4.51M), including a CFO sale that reduced his stake by ~75%.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s share price dropped 6.5% during mid-day trading on Friday . The stock traded as low as $31.39 and last traded at $31.3950. Approximately 545,932 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 1,262,229 shares. The stock had previously closed at $33.58.

Analyst Ratings Changes

CAPR has been the subject of several recent analyst reports. B. Riley Financial increased their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Friday, March 13th. Piper Sandler restated an "overweight" rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, January 11th. HC Wainwright reiterated a "buy" rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Finally, Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an "overweight" rating in a report on Friday, March 13th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.09.

Capricor Therapeutics Stock Down 8.0%

The firm has a market capitalization of $1.79 billion, a P/E ratio of -13.68 and a beta of 0.48. The stock has a fifty day moving average of $31.11 and a 200-day moving average of $22.54.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post 0.01 EPS for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 147,529 shares of company stock valued at $4,509,940. 9.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new position in Capricor Therapeutics during the third quarter valued at approximately $1,555,000. Moody Aldrich Partners LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $6,025,000. Pier Capital LLC boosted its position in Capricor Therapeutics by 35.0% during the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company's stock valued at $3,580,000 after purchasing an additional 128,837 shares during the last quarter. AlphaQuest LLC boosted its position in Capricor Therapeutics by 396.2% during the third quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company's stock valued at $216,000 after purchasing an additional 23,974 shares during the last quarter. Finally, HBK Sorce Advisory LLC boosted its position in Capricor Therapeutics by 19.4% during the fourth quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company's stock valued at $5,879,000 after purchasing an additional 33,128 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.